Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Michael R Migden"'
Autor:
Aleksandar Sekulic, Michael R. Migden, Nicole Basset-Seguin, Claus Garbe, Anja Gesierich, Christopher D. Lao, Chris Miller, Laurent Mortier, Dedee F. Murrell, Omid Hamid, Jorge F. Quevedo, Jeannie Hou, Edward McKenna, Natalie Dimier, Sarah Williams, Dirk Schadendorf, Axel Hauschild, for the ERIVANCE BCC Investigators
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-10 (2017)
BMC Cancer
BMC Cancer
In the primary analysis of the ERIVANCE BCC trial, vismodegib, the first US Food and Drug Administration–approved Hedgehog pathway inhibitor, showed objective response rates (ORRs) by independent review facility (IRF) of 30% and 43% in metastatic b
Autor:
Ruth Plummer, Martin Kaatz, Alexander Guminski, Patrick Combemale, Karl D. Lewis, Ragini R. Kudchadkar, Manisha Mone, Dalila Sellami, Jocelyn Zhou, Carmen Loquai, Luc Dirix, Anne Lynn S. Chang, Ralf Gutzmer, John T. Lear, Tingting Yi, Michael R. Migden, Reinhard Dummer, Alexandros Stratigos, Uwe Trefzer, Henry Castro
Publikováno v:
Journal of the European Academy of Dermatology and Venereology
Background Patients with locally advanced basal cell carcinoma (laBCC) or metastatic BCC (mBCC), two difficult-to-treat populations, have had limited treatment options. Sonidegib, a hedgehog pathway inhibitor (HPI), was approved in laBCC based on res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2c71a42ca781cb5725f0ad8c828de1c
https://www.zora.uzh.ch/id/eprint/143585/
https://www.zora.uzh.ch/id/eprint/143585/
Autor:
Ralf Gutzmer, Tingting Yi, Alexander Guminski, Hans Joachim Schulze, Alexander J. Stratigos, Carmen Loquai, Patrick Combemale, Anne Lynn S. Chang, R. Herd, Ragini R. Kudchadkar, Ruth Plummer, Dalila Sellami, Frank Cornelis, Luc Dirix, Michael R. Migden, Reinhard Dummer, Sven Gogov, Karl D. Lewis, John T. Lear, Celine Pallaud, Manisha Mone, Martin Kaatz, Uwe Trefzer
Summary Background Patients with advanced basal cell carcinoma have limited treatment options. Hedgehog pathway signalling is aberrantly activated in around 95% of tumours. We assessed the antitumour activity of sonidegib, a Hedgehog signalling inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a068ac7f39ea8f9f41d63de9159e17b
https://doi.org/10.5167/uzh-113018
https://doi.org/10.5167/uzh-113018
Autor:
Aleksandar Sekulic, James A. Solomon, Simon Yoo, Karl D. Lewis, John D. Hainsworth, Huibin Yue, Luc Dirix, Axel Hauschild, Sarah T. Arron, Anne Lynn S. Chang, Ellen S. Marmur, Jeannie Hou, Michael R. Migden, Charles M. Rudin, Philip Friedlander
Publikováno v:
Journal of the American Academy of Dermatology. 72(6)
Background Primary analysis from the pivotal ERIVANCE BCC study resulted in approval of vismodegib, a Hedgehog pathway inhibitor indicated for treatment of adults with metastatic or locally advanced basal cell carcinoma (BCC) that has recurred after
Autor:
Michael R. Migden, Anne Lynn S. Chang, Karl D. Lewis, Celine Pallaud, Luc Dirix, Frank Cornelis, Manisha Mone, Reinhard Dummer, Sven Gogov, John T. Lear, Martin Kaatz, Ruth Plummer, Patrick Combemale, Uwe Trefzer, Ralf Gutzmer, Alexander Guminski, Carmen Loquai, Dalila Sellami, Alexander J. Stratigos, Ragini R. Kudchadkar, Tingting Yi, R. Herd, Hans Joachim Schulze
Publikováno v:
Journal of the American academy of dermatology, Vol. 75, no.1, p. 113-125.e5 (2016)
Background The hedgehog pathway inhibitor sonidegib demonstrated meaningful tumor shrinkage in more than 90% of patients with locally advanced basal cell carcinoma (BCC) or metastatic BCC in the BCC Outcomes with LDE225 Treatment study. Objective Thi
Autor:
Josina C. Reddy, Anne Lynn S. Chang, Michael R. Migden, Charles M. Rudin, John D. Hainsworth, Howard Mackey, Anthony E. Oro, Karl D. Lewis, Philip Friedlander, Axel Hauschild, Sarah T. Arron, Robert L. Yauch, Richard A. Graham, Jennifer A. Low, Simon Yoo, Luc Dirix, James A. Solomon, Aleksandar Sekulic, Ellen S. Marmur
Publikováno v:
The New England journal of medicine. 366(23)
Alterations in hedgehog signaling are implicated in the pathogenesis of basal-cell carcinoma. Although most basal-cell carcinomas are treated surgically, no effective therapy exists for locally advanced or metastatic basal-cell carcinoma. A phase 1 s